Results for tag: "Eloctate"

The Eloctate market is a subset of the hematological drugs market, which includes drugs used to treat blood-related diseases. Eloctate is a recombinant factor VIII therapy used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Eloctate is a long-acting therapy, meaning it can be administered less frequently than other factor VIII therapies. It is also the first factor VIII therapy to be approved for use in children under 12 years of age. Eloctate is a relatively new therapy, and is currently the only long-acting factor VIII therapy on the market. It is manufactured by Biogen, a biotechnology company based in the United States. Other companies in the hematological drugs market include Novo Nordisk, Bayer, Pfizer, and Shire. Show Less Read more